IRIS
VALENTINI, Gabriele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 23.247
NA - Nord America 6.823
AS - Asia 5.203
SA - Sud America 1.204
AF - Africa 69
Continente sconosciuto - Info sul continente non disponibili 18
OC - Oceania 4
Totale 36.568
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 9.452
IT - Italia 7.579
US - Stati Uniti d'America 6.653
SG - Singapore 1.947
IE - Irlanda 1.848
CN - Cina 1.145
UA - Ucraina 1.123
BR - Brasile 1.052
HK - Hong Kong 1.011
GB - Regno Unito 840
DE - Germania 611
FR - Francia 565
FI - Finlandia 288
VN - Vietnam 282
SE - Svezia 252
NL - Olanda 234
TR - Turchia 211
GR - Grecia 196
KR - Corea 157
IN - India 149
CA - Canada 111
BE - Belgio 71
JP - Giappone 69
AR - Argentina 54
ES - Italia 47
ID - Indonesia 44
BD - Bangladesh 35
MX - Messico 33
IQ - Iraq 32
EC - Ecuador 29
PL - Polonia 29
CH - Svizzera 27
AT - Austria 26
ZA - Sudafrica 22
CO - Colombia 20
PY - Paraguay 16
UZ - Uzbekistan 16
PK - Pakistan 13
EU - Europa 12
MA - Marocco 11
RO - Romania 11
TH - Thailandia 10
VE - Venezuela 10
CZ - Repubblica Ceca 9
EG - Egitto 9
TW - Taiwan 9
UY - Uruguay 9
CL - Cile 8
HR - Croazia 8
HU - Ungheria 8
KZ - Kazakistan 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
KE - Kenya 6
TN - Tunisia 6
AZ - Azerbaigian 5
BH - Bahrain 5
BY - Bielorussia 5
IR - Iran 5
PE - Perù 5
CR - Costa Rica 4
DZ - Algeria 4
JO - Giordania 4
KG - Kirghizistan 4
NP - Nepal 4
PA - Panama 4
PH - Filippine 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
BB - Barbados 3
IL - Israele 3
JM - Giamaica 3
NI - Nicaragua 3
RS - Serbia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
DK - Danimarca 2
ET - Etiopia 2
HN - Honduras 2
LB - Libano 2
LT - Lituania 2
MK - Macedonia 2
MY - Malesia 2
NO - Norvegia 2
OM - Oman 2
PT - Portogallo 2
QA - Qatar 2
SY - Repubblica araba siriana 2
AO - Angola 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CI - Costa d'Avorio 1
DO - Repubblica Dominicana 1
GE - Georgia 1
Totale 36.557
Salva come PNG Salva come JPEG
Città #
Moscow 3.275
Dublin 1.841
Jacksonville 1.575
Hong Kong 1.008
Santa Clara 807
Chandler 756
Singapore 622
Rome 507
Milan 420
Princeton 288
Medford 254
Ashburn 225
Beijing 200
Ann Arbor 166
Naples 156
Napoli 156
San Mateo 152
Seoul 152
Boardman 148
Roxbury 148
Wilmington 138
Hefei 126
Bremen 113
Woodbridge 113
Ho Chi Minh City 111
Bengaluru 100
Florence 89
Turin 89
Palermo 86
Cambridge 83
Dallas 72
São Paulo 68
Hanoi 67
Catania 64
Des Moines 64
Mountain View 64
Brussels 62
Bari 59
Caserta 58
The Dalles 55
Bologna 53
Ottawa 52
Padova 50
Nanjing 49
New York 44
Verona 39
Genoa 34
Munich 33
Rio de Janeiro 31
Torino 27
Brasília 26
Helsinki 26
Los Angeles 25
Belo Horizonte 24
Cagliari 24
Taranto 24
Mcallen 23
Pescara 23
Messina 22
Toronto 22
Houston 21
Jinan 21
Nuremberg 21
Redwood City 21
Venice 21
Guangzhou 20
Livorno 20
Brescia 19
Parma 19
Vicenza 19
France 18
Genova 18
Perugia 18
Düsseldorf 17
Kunming 17
London 17
Modena 17
Norwalk 17
Salerno 17
Trieste 17
Baghdad 15
Changsha 15
Curitiba 15
Gorno 15
Reggio Emilia 15
Auburn Hills 14
Reggio Calabria 14
Tashkent 14
Campinas 13
Falls Church 13
Hebei 13
Salvador 13
Da Nang 12
Dhaka 12
Guarulhos 12
Montréal 12
Ningbo 12
Ribeirão Preto 12
Shanghai 12
Trento 12
Totale 15.828
Salva come PNG Salva come JPEG
Nome #
ARTRITE PSORIASICA ED INTERSTIZIOPATIA POLMONARE : DESCRIZIONE DI UN CASO CLINICO. 7.938
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group 439
ANTI TNF ALFA IN PAZIENTI AFFETTI DA ARTRITE REUMATOIDE E SPONDILOARTRITI HBV CARRIERS OCCULTI:STUDIO RETROSPETTIVO SULLA SICUREZZA 289
A PILOT STUDY ON LOW-DOSE INTRAVENOUS CICLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS: EFFICACY, SAFETY AND EFFECTS ON CELLULAR ACTIVATION MARKERS 197
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 180
Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes 177
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 175
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 172
ANTI-TNFα TREATMENT IS ASSOCIATED WITH INCREASED LIVER STIFFNESS IN HBV OCCULT CARRIER PATIENTS 171
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 155
[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis] 153
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 150
[T-lymphocyte subpopulations in the conjunctiva of subjects with secondary Sjogren's syndrome] 150
[HAQ-DI Italian version in systemic sclerosis]. 147
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 146
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 145
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis 141
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 139
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 139
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population 138
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 137
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 137
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis 136
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 136
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 135
Alterazione del riempimento ventricolare sinistro nella sclerosi sistemica (SSc): risultati di uno studio Iongitudinale 135
.ANTI-TNF alfa IN PATIENTS WITH EITHER RHEUMATOID ARTHRITIS OR SPONYLOATHRITIS And CONCURRENT C HEPATITIS:A RETROSPECTIVE RECORD REVIEW ON SAFETY 135
ARTHRITIS IS ASSOCIATED WITH PSORIASIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES 134
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus 131
[Eosinophilic fasciitis. A recently reported oligotopic connective tissue inflammation. A case report] 129
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study 129
Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study 129
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation 128
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 128
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 126
Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause 126
Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease 125
[Hypocomplementemia in systemic sclerosis]. 125
Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography 124
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 124
[Absolute and relative increase in Leu-11b+ cells in patients with systemic scleroderma] 124
A SCLERODERMA PATIENT WITH SWOLLEN AND TENDER JOINTS OF BOTH HANDS 124
[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]. 123
PREVALENCE OF ANTIBODIES RECOGNAIZING CYCLIC CITRULLINATED PEPTIDE(anti CCP) IN PATIENTS WITH ULCERATIVE COLITIS 122
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes 122
[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability]. 121
Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis 120
[Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study]. 119
Evidence for peripheral impaired glucose handling in patients with connective tissue diseases 119
Cardiac involvement in rheumatoid arthritis: an echocardiographic study 119
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 118
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 118
ANTI-TOPOISOMERASE I (ANTI-SCL-70) AND CANCER IN SYSTEMIC SCLEROSIS. ARE THEY RELATED? 116
Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study 116
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. 115
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 115
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 115
Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence. 114
Alterazioni del sistema nervoso autonomo nella Sclerosi Sistemica (SSc). Risultati preliminari di uno studio sul rapporto con la severita della malattia 114
[Metabolic syndrome in inflammatory rheumatic diseases]. 114
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study 113
Impaired exercise performance in systemic sclerosis and its clinical correlations 113
.Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. 113
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. 113
Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. 112
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 112
[Rarity of sclerodermic renal crisis in the Italian population and the uncommon nature of the Vogt-Koyanagi-Harada syndrome in systemic sclerosis] 112
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients 111
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 111
ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. 111
RELATIONSHIP OF THE 6-MIN WALKING TEST AND QUALITY OF LIFE 111
Crioglobulinemia mista essenziale: prevalenza e caratteri della neuropatia periferica 110
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 110
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database 109
RELAPSING POLYCHONDRITIS. AN HYSTOCHEMICAL STUDY BY LECTIN. 109
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 109
Brief report: Successful pregnancies but a higher risk of preterm births in systemic sclerosis: An Italian multicentric study. 109
Severe polymyositis due to Toxoplasma gondii in an adult immunocompetent patient: a case report and review of the literature. 109
ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS: EVALUATION OF INTIMA-MEDIA THICKNESS AND CORRELATION WITH INFLAMMATORY AND ATHEROGENIC MARKERS 109
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative 109
Cell-free DNA in the plasma of patients with systemic sclerosis 108
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group 108
Glucocorticoids in systemic sclerosis: weighing the benefits and risks - a systematic review 108
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 108
VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) AND DAS28 AS MEASURE OF RESPONSE TO TREATMENT IN PATIENTS UNDERGOING DIFFERENT THERAPEUTIC REGIMENS 108
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 108
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study 107
Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve 106
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 106
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 106
[The arthropathy of systemic sclerosis]. 106
The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: Implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRRCS study 106
New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. 105
Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries 105
Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study 105
Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group 105
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis. 105
Thrombocytosis in progressive generalized sclerosis (scleroderma) and in other rheumatic diseases 104
Systemic sclerosis 104
Early systemic sclerosis: short –term disease evolution and factors predidting the development of new manifestations of organ involvement 104
Totale 20.655
Salva come PNG Salva come JPEG
Categoria #
all - tutte 111.560
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 111.560
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.767 0 0 0 0 0 111 381 316 137 363 312 147
2021/20222.634 245 77 93 103 738 103 106 162 134 120 201 552
2022/20234.527 430 195 113 303 394 316 112 297 1.767 184 204 212
2023/20242.785 195 131 182 285 626 109 189 230 130 161 228 319
2024/20255.492 125 162 120 195 715 859 820 459 612 803 381 241
2025/202613.282 526 591 852 893 1.372 9.048 0 0 0 0 0 0
Totale 37.165